A Dose Determination and Safety Study of X4P-001 (Mavorixafor) in Participants With Warts, Hypogammaglobulinemia, Infections, and Myelokathexis (WHIM) Syndrome
Clinical trial NCT03005327 · COMPLETED
Trial details
- NCT number
- NCT03005327
- Sponsor
- X4 Pharmaceuticals
- Status
- COMPLETED
- Phase
- Phase 2
- Study type
- INTERVENTIONAL
- Start date
- 2016-12-01
- Primary completion
- 2022-06-16
- Enrollment
- 8
Track trials programmatically
Sponsors, conditions and status changes through the Atlas API.